product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
MDM2
catalog :
86934
clonality :
monoclonal
conjugate :
nonconjugated
clone name :
D1V2Z
reactivity :
human
application :
western blot
citations: 2
Published Application/Species/Sample/DilutionReference
  • western blot; human; loading ...; fig 3b
Ng S, Yoshida N, Christie A, Ghandi M, Dharia N, Dempster J, et al. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018;9:2024 pubmed publisher
Stolte B, Iniguez A, Dharia N, Robichaud A, Conway A, Morgan A, et al. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. J Exp Med. 2018;215:2137-2155 pubmed publisher
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
https://www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.